Alkermes announced new developments related to its late-stage product candidates in its proprietary central nervous system pipeline. The company unveiled aripiprazole lauroxil two-month, a new product candidate addition to its portfolio of atypical antipsychotics for the treatment of schizophrenia. This new two-month product candidate is designed to provide physicians and patients with a longer dosing option than the once-monthly formulation of aripiprazole lauroxil, which is currently completing the phase 3 study, with topline results expected in 1H14. In addition, Alkermes provided details regarding its pivotal phase 3 program for ALKS 5461, a Fast Track-designated new medicine being evaluated for the treatment of major depressive disorder (MDD) in patients who have had an inadequate response to standard therapies. The phase 3 trials for ALKS 5461 is expected to begin in the first quarter of 1Q14. Alkermes plans to begin clinical testing in 2014 for aripiprazole lauroxil